Floatz logo

Carboplatin

Advance Solid Tumors

SanofiSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Advance Solid Tumors cohort.

Asset / SponsorPhaseRating
Inv-8989
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1/2CCC
Iniparib
Sanofi
Phase 1CC
Alk-N001 For
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Phase 1CC
Kivu-107
Kivu Bioscience Inc.
Phase 1CC

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →